The genetics industry provides data that life science companies need to make new products. Here’s a look at the largest genetics stocks.
From diagnostics to drug development, the genetics industry provides information that biotechnology, pharmaceutical and medical device companies need to continue making innovative products. The largest genetics stocks are responsible for these advances.
That’s why we’re counting down some significant players in genetics and genomics — companies that splice and edit their days away, developing technologies and tests that are key for the life science sector.
The following seven companies specialize in different areas and work on a range of innovative products. Without further ado, here are the seven largest genetics stocks to watch. The companies below are listed in order of market cap, and all information was current at the time of publication.
1. Seattle Genetics (NASDAQ:SGEN)
Market cap: US$26.12 billion
Seattle Genetics is first on our list of largest genetics stocks. It describes itself as an “emerging multi-product, global biotechnology company.” This comparatively new firm develops and commercializes cancer-related therapies. Its flagship product is Adcetris, which is approved for the treatment of several types of CD30-expressing lymphomas, among other cancers.
The company’s areas of research include antibody-drug conjugate technology and sugar-engineered antibody technology. It has numerous products in its pipeline, and says it is focused on further expanding Adcetris, as well as addressing “significant unmet medical needs” through a new generation of targeted, empowered therapies.
2. EXACT Sciences (NASDAQ:EXAS)
Market cap: US$13.64 billion
EXACT Sciences is a molecular diagnostics company that specializes in the early detection and prevention of colorectal cancer.
In 2014, the company launched Cologuard, which is the first stool DNA test for colorectal cancer.
3. Bluebird bio (NASDAQ:BLUE)
Market cap: US$4.47 billion
Bluebird bio, which has its headquarters in Cambridge, Massachusetts, is developing a number of gene therapies to treat severe genetic diseases and cancer.
The company is currently conducting clinical trials of investigational gene therapies in four diseases, including transfusion-dependent β-thalassemia, severe sickle cell disease, cerebral adrenoleukodystrophy and relapsed/refractory multiple myeloma.
4. Natera (NASDAQ:NTRA)
Market cap: US$3.37 billion
Natera is a genetics testing and diagnostics company. A key area of focus for Natera is developing non-invasive ways of analyzing DNA. Over the last 10 years, the company has introduced 10 molecular screening tests and runs thousands of genetic tests each month through its laboratory.
Natera’s areas of focus include reproductive health, organ transplantation and cancer. Its genetic testing services, which use its cloud-based software platform, are aimed at educating biopharmaceutical company researchers, physicians who treat pregnant women and genetic laboratories.
5. Invitae (NYSE:NVTA)
Market cap: US$2.28 billion
Invitae is a genetics information company that aims to push the field of medicine at large to use genetic testing and information to create personalized medicine, treatments that are more specific and preventative procedures.
The firm specializes in genetic diagnostics and has a vast portfolio that holds software tools, laboratory processes, genetics testing and analysis, to name a few. Invitae has diagnostic tests for hereditary cancer, metabolic disorders, neurological and cardiovascular disorders, pediatric and developmental disorders, as well as miscarriage analysis and preimplantation and carrier screening for inherited disorders.
6. Veracyte (NASDAQ:VCYT)
Market cap: US$1.35 billion
Veracyte is a genomic diagnostics company that combines advanced genomic technology, clinical science and machine learning into its products. The company claims this approach helps doctors and patients be informed of diagnosis and treatment options without the risk of surgery.
Veracyte was founded over a decade ago and, since then, has commercialized five genomic tests that are helping diagnose thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
7. Myriad Genetics (NASDAQ:MYGN)
Market cap: US$1.21 billion
Myriad Genetics has been around a long time — it was founded in 1991, before the human genome was sequenced. The company specializes in molecular diagnostics, and its products include molecular tests for hereditary and urological cancers, autoimmune disorders, depression and other diseases.
The company currently has 14 tests on the market and 12 diagnostic tests in its pipeline, eight of which are in Stage 3, meaning they are on the cusp of deployment. The tests span a large spectrum and relate to dermatology, oncology, urology, women’s health and autoimmune diseases, among other things.
This is an updated version of an article originally published by the Investing News Network in 2016.
Don’t forget to follow us @INN_LifeScience for real-time news updates.larges
Securities Disclosure: I, Nicole Rashotte, hold no direct investment interest in any company mentioned in this article.